TY - JOUR
T1 - Advances in microfluidics for lipid nanoparticles and extracellular vesicles and applications in drug delivery systems
AU - Maeki, Masatoshi
AU - Kimura, Niko
AU - Sato, Yusuke
AU - Harashima, Hideyoshi
AU - Tokeshi, Manabu
N1 - Funding Information:
This work was supported by a Core Research Evolutional Science and Technology (CREST) project from the Japan Science and Technology Agency (JST) ( JP17937657 ). A part of this work was also supported by the Tokyo Kasei Chemical Promotion Foundation .
Publisher Copyright:
© 2018 Elsevier B.V.
PY - 2018/3/15
Y1 - 2018/3/15
N2 - Lipid-based nanobiomaterials as liposomes and lipid nanoparticles (LNPs) are the most widely used nanocarriers for drug delivery systems (DDSs). Extracellular vesicles (EVs) and exosomes are also expected to be applied as DDS nanocarriers. The performance of nanomedicines relies on their components such as lipids, targeting ligands, encapsulated DNA, encapsulated RNA, and drugs. Recently, the importance of the nanocarrier sizes smaller than 100 nm is attracting attention as a means to improve nanomedicine performance. Microfluidics and lab-on-a chip technologies make it possible to produce size-controlled LNPs by a simple continuous flow process and to separate EVs from blood samples by using a surface marker, ligand, or electric charge or by making a mass or particle size discrimination. Here, we overview recent advances in microfluidic devices and techniques for liposomes, LNPs, and EVs and their applications for DDSs.
AB - Lipid-based nanobiomaterials as liposomes and lipid nanoparticles (LNPs) are the most widely used nanocarriers for drug delivery systems (DDSs). Extracellular vesicles (EVs) and exosomes are also expected to be applied as DDS nanocarriers. The performance of nanomedicines relies on their components such as lipids, targeting ligands, encapsulated DNA, encapsulated RNA, and drugs. Recently, the importance of the nanocarrier sizes smaller than 100 nm is attracting attention as a means to improve nanomedicine performance. Microfluidics and lab-on-a chip technologies make it possible to produce size-controlled LNPs by a simple continuous flow process and to separate EVs from blood samples by using a surface marker, ligand, or electric charge or by making a mass or particle size discrimination. Here, we overview recent advances in microfluidic devices and techniques for liposomes, LNPs, and EVs and their applications for DDSs.
UR - http://www.scopus.com/inward/record.url?scp=85045474057&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85045474057&partnerID=8YFLogxK
U2 - 10.1016/j.addr.2018.03.008
DO - 10.1016/j.addr.2018.03.008
M3 - Review article
C2 - 29567396
AN - SCOPUS:85045474057
SN - 0169-409X
VL - 128
SP - 84
EP - 100
JO - Advanced Drug Delivery Reviews
JF - Advanced Drug Delivery Reviews
ER -